Drug intelligence / Profile preview

9D9

Development stage: Preclinical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

9D9 is an experimental monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). It is designed to block the inhibitory signal mediated by CTLA-4, thereby enhancing T-cell activation and promoting anti-tumor immune responses. This mechanism is similar to that of other anti-CTLA-4 antibodies such as ipilimumab. The antibody has been described in preclinical research and patent literature as a tool for localized expression or delivery of anti-CTLA-4 activity, potentially for cancer immunotherapy applications[7].

Targets

CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)

Beyond the preview

Go deeper on 9D9.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 9D9.

Explore the full profile